GlassScriptPhysician profile
Peter Chiotellis
NPI 1275793952
$7,434.99
in general payments reported to CMS, 2019-2025
29 companies · $881 in 2025
The $881 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $673 · 2021: $1,888 · 2022: $759 · 2023: $961 · 2024: $1,213 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,094.41 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $788.02 | 2019-2025 | |
| Welch Allyn | $787.50 | 2021 | |
| Amgen INC. | $548.21 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $507.81 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $474.69 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $356.88 | 2019-2025 | Watchman, Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.97 | 2019-2025 | Jardiance |
| Pfizer INC. | $288.60 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $266.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $266.19 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $242.31 | 2020-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $220.68 | 2019-2025 | Farxiga |
| Heartflow, INC. | $207.70 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.38 | 2019-2025 | Lifevest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $155.29 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $145.27 | 2019-2021 | |
| Scpharmaceuticals INC. | $102.36 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $97.48 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $67.02 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $61.14 | 2022-2025 | Evkeeza |
| Abbott Laboratories | $55.25 | 2024 | Cardiomems |
| Gilead Sciences, INC. | $44.62 | 2019 | |
| Edwards Lifesciences Corporation | $41.80 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $41.07 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $37.07 | 2023-2024 | Inpefa |
| Abiomed | $22.19 | 2024 | Impella |
| Alexion Pharmaceuticals, INC. | $13.22 | 2019 | |
| Medtronic Vascular, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chiotellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.